B
iliary atresia (BA), a major cause of obstructive jaundice in infants, is a congenital obliterative cholangiopathy of unknown aetiology. 1 The incidence of BA is approximately one in 15,000 live births worldwide. 2 Aggressive and rapid progression of hepatic fibrosis is a universal and prominent characteristic of BA. If left untreated, this process invariably leads to cirrhosis, liver failure, and even death. At present, Kasai portoenterostomy is the first-line therapy for BA. 3 Previous studies have suggested that the severity of preoperative fibrosis is a major predictor in evaluation of the disease prognosis. 4 The evaluation of liver fibrosis is a key indicator for the necessity of liver transplantation in children with BA. 5 Thus, accurate assessment of liver fibrosis is of great importance. Currently, liver biopsy for fibrosis assessment based on pathological scoring system is still considered as the gold standard. However, this procedure is invasive and may result in unavoidable complications and sampling errors. 6, 7 These limitations have led to an increasing demand for a noninvasive and effective method as an important adjunct to the liver biopsy.
As a novel and potentially noninvasive method for the assessment of liver fibrosis, acoustic radiation force impulse (ARFI) imaging is based on the measurement of shear wave speeds (SWSs) generated by mechanically exciting liver tissue with use of short-duration acoustic pulses. In the last decade, a number of studies [8] [9] [10] [11] [12] [13] have been published that evaluate the performance of ARFI imaging for adults with chronic liver diseases, indicating that ARFI imaging was a promising method in assessing the severity of liver fibrosis.
To date, a few studies have considered the application of this technique in children, [14] [15] [16] and one of them focused on eight postoperative children with BA ranging from 1 to 31 months. 17 To the best of our knowledge, no research has concerned ARFI imaging for the preoperative fibrosis evaluation in BA infants so far. The primary purpose of our study was to investigate the diagnostic performance of ARFI imaging in assessing liver fibrosis in the preoperative setting of infants with BA.
Materials and Methods

Patients
This study was approved by the ethics committee of Xinhua Hospital, affiliated with the Shanghai Jiaotong University School of Medicine (approval No. XHEC-D-2015-160), and was in accordance with the Helsinki Declaration of 1975. Written informed consent was obtained from each infant's guardians before the examination. Between October 2012 and May 2015, 53 consecutive infants with hyperbilirubinemia confirmed to have BA by cholangiography were enrolled in our study. The inclusion criteria of the BA group were an effective liver biopsy and the interval of less than 3 days from ARFI examination to liver biopsy. The exclusion criterion was an inadequate specimen for liver fibrosis staging. During the same period, 50 healthy infants serving as controls were included. The inclusion criteria of the healthy group were negative findings based on conventional ultrasound liver scanning, negative routine liver function tests, and the absence of any known hepatobiliary disease history. The exclusion criterion was a history of taking any medication.
Acoustic Radiation Force Impulse Imaging Acoustic radiation force impulse imaging was performed within 3 days before cholangiography and liver biopsy in the ultrasound examination room. The infants were sedated by taking chloral hydrate orally at a dose of 50 mg/kg body weight, 30 minutes before the examination, and were in the fasting state for at least 4 hours. Acoustic radiation force impulse imaging was performed by a 5-year experienced sonographer in pediatric disease, who was blinded to any clinical data. The examination used a Siemens Acuson S2000 (Siemens Medical Solutions, Mountain View, CA) with a 4-to 9-MHz linear transducer (a 7-MHz center frequency was used in this study). Virtual Touch Quantification mode was used to measure the SWSs after conventional ultrasound liver scanning. The region of interest was a fixed 5 3 6 mm box that was placed in the right liver lobe approximately 2 cm under the liver capsule, away from visible vessels and bile ducts, using an intercostal approach ( Figure 1 ). Each SWS was obtained per image acquisition at the end of inspiration, displayed in the right side of the screen. The result was expressed in meters per second (m/s). Once "X-X-X" was displayed on the screen, as a result of considerable movement of the liver due to respiration during sampling, the measurement was invalid. After the examination, a total of 10 valid measurements were obtained from each infant and the median values were calculated for further analysis.
Liver Biopsy Analysis
In the operating room, all infants first underwent a cholangiography, then the liver biopsy was performed immediately using a 16-gauge automatic biopsy needle under ultrasonographic guidance. The interval between liver biopsy and ARFI imaging was less than 3 days. A minimum of two biopsy specimens were acquired from each BA infant. The specimens were routinely formalin-fixed, paraffin-embedded, and stained with hematoxylin-eosin and Masson's trichrome stains. These biopsies were assessed by a 10-year experienced pathologist in hepatopathology, who was blinded to the clinical data. Samples containing at least six portal tracts and at least 15 mm in length were defined as adequate. According to the Batts-Ludwig scoring system, 18 liver fibrosis was classified into five stages: F0, no fibrosis; F1, portal fibrosis; F2, periportal fibrosis or rare portal-portal septa; F3, septal fibrosis with architectural distortion but no obvious cirrhosis; and F4, cirrhosis. A score of F 5 0-1 was defined as no or mild fibrosis, F 2 as significant fibrosis, F 3 as severe fibrosis, and F 5 4 as cirrhosis.
Statistical Analysis
Statistical analyses were performed using the SPSS software, version 20.0 (IBM Corp, Chicago, IL). Correlation among SWS, tissue pathology fibrosis stage, and age were analyzed with the Spearman rank correlation analysis or Pearson correlation analysis whenever appropriate. The Mann-Whitney U test and student t test were used to compare SWSs between fibrosis groups whenever appropriate. In addition, receiver operating characteristic (ROC) curves were constructed, and the cut-off values for the diagnosis of significant fibrosis (F 2), severe fibrosis (F 3), and cirrhosis (F 5 4) were determined by optimization of the Youden index. The sensitivity, specificity, positive predictive value, negative predictive value, and area under the receiver operating characteristic curve (AUROC) were also calculated. Results were considered statistically significant if the P values were less than 0.05.
Results
A total of 53 BA infants and 50 healthy infants were included in this study. Three cases of BA were excluded because of an inadequate specimen for liver fibrosis staging. The characteristics of 50 BA infants and 50 healthy infants are provided in Table 1 . There was no significant difference between the BA group and the healthy group according to gender (P 5 .685) and age (P 5 .535).
The mean SWS in the BA group was 1.89 6 0.45 m/s (range: 1.02-3.47 m/s), which is significantly higher than that in controls (1.12 6 0.06 m/s, range: 1.01-1.27 m/s) (P < .001). A positive correlation was observed in the BA group between SWS and fibrosis stage (r 5 0.719, P < .001), between SWS and age (r 5 0.603, P < .001), and between fibrosis stage and age (r 5 0.501, P < .001), whereas there was no correlation in the healthy group between SWS and age (r 5 2 0.093, P 5 .519).
According to the pathologic staging results, 2 BA infants were classified in F0, 11 in F1, 18 in F2, 11 in F3, 8 in F4, and the mean SWS for each stage was 1.10 6 0.11, 1.62 6 0.23, 1.76 6 0.27, 2.05 6 0.28, and 2.51 6 0.50 m/s, respectively. The SWS showed a gradually increasing tendency from F0 to F4. When comparing SWSs between consecutive fibrosis stages from F0 to F4, significant differences were found with the exception between F1 and F2 (P 5 .144), whereas there was a statistical difference between F0-F1 and F2 (P 5 .042). Figure 2 shows a box and whisker plot of SWSs for the healthy group and the BA group versus fibrosis stage. Table 2 gives the descriptive statistics of SWSs in the healthy group and the BA group for each fibrosis stage, as well as tests comparing SWSs between each consecutive fibrosis stage.
According to the definition of no or mild fibrosis (F 5 0-1), significant fibrosis (F 2), severe fibrosis (F 3), and cirrhosis (F 5 4), 13 BA infants were classified in the no or mild fibrosis group, 37 in the significant fibrosis group, 19 in the severe fibrosis group, and 8 in the cirrhosis group. The mean SWSs were 1.54 6 0.29, 2.01 6 0.44, 2.25 6 0.44, and 2.51 6 0.50 m/s, respectively, showing a gradually increasing tendency, and there was a significant difference among the four groups (P < .05). Table 3 presents the descriptive statistics and statistical analysis of SWSs in each fibrosis group. The ROC curves were constructed to determine the cut-offs that predict significant fibrosis, severe fibrosis, and cirrhosis ( Figure 3) . The optimal cut-offs for diagnosis of each group were 1.53, 1.80 and 2.16 m/s, respectively, and the AUROCs were 0.823, 0.884 and 0.917, respectively. Table 4 lists the corresponding AUROC, sensitivity, specificity, positive predictive value, and negative predictive value for each cut-off.
Discussion
A number of pediatric liver diseases are accompanied by the development of liver fibrosis. Compared with other liver diseases, BA is a destructive inflammatory obliterative cholangiopathy, accompanied by intrahepatic cholestasis, portal inflammation, and bile ductular proliferation, so the liver fibrosis progresses extremely rapidly, often within a few months. [19] [20] [21] The results of our study confirmed this disease evolution, as we found a positive correlation between liver fibrosis stage and age in infants with BA (r 5 0.501, P < .001). Because of the rapid progression of liver fibrosis and the limitation of previous blood tests or imaging techniques, liver fibrosis had already developed to end stage at the time of disease detection. However, in recent years the development of blood tests and imaging techniques, such as a2-macroglobulin, haptoglobin, hyaluronic acid and ultrasound examination, have made a significant improvement in the early diagnosis of BA. [22] [23] [24] The degree of liver fibrosis in BA infants is of great importance for outcome prediction, prognosis evaluation, and even clinical management. 4, [25] [26] [27] Lower fibrosis scores usually correlated with better prognoses, and delay liver transplantation. 4 Otherwise, once severe fibrosis or cirrhosis was detected preoperatively, the restoration of liver damage was limited after Kasai, and these infants have less chance of getting benefit from the Kasai procedure, active consideration should be given to early liver transplantation. 25, 26 Besides, for infants with an excessively late diagnosis or advanced cirrhosis, direct liver transplantation rather than Kasai may be considered, even though Kasai is the standard first procedure for biliary atresia currently. 27 Consequently, it brings to light the clinical need for the detection and quantification of liver fibrosis as well as assessment of progression of fibrosis over time in infants with BA.
Acoustic radiation force impulse imaging, as a novel technique in the assessment of liver stiffness, is appealing for patients with liver fibrosis, and has great potential in clinical application because it is noninvasive, painless, and reproducible. In recent years, a few studies concerning the application of this technique in children were published. For instance, the study by Hanquinet et al reported the congruence between SWSs and fibrosis stage in children with chronic liver diseases or liver transplants by showing that SWSs increased with the increasing stage of liver fibrosis in children ranging from 1 month to 17 years old. 15 A significant correlation between SWSs and fibrosis stages (r 5 0.719, P < .001) was also found in our study. Both studies' overall trends were similar; however, the mean SWSs for each fibrosis stage in their study were slightly higher than ours. A possible reason for this result discrepancy may be the difference in diseases included in both studies. Although there was some degree of overlap between neighboring fibrosis stages in SWSs, a significant difference was still found with the exception of differences between F1 and F2 (P 5 .144). This is in accordance with the fact that according to the Batts-Ludwig scoring system the pathological difference between F1 and F2 is not very large in BA infants. Because unlike other chronic liver diseases, portal fibrosis and the expansion of BA infants in F1 stage is conspicuous and very serious before periportal fibrosis or rare portal-portal septa appears, which refers to the F2 stage.
Previous studies have shown that significant fibrosis (F 2) is an important marker of progressive liver disease. 28 In other words, compared with the infants with no or mild fibrosis (F0-F1), patients with significant fibrosis or above are at an increased risk for developing subsequent complications of severe liver fibrosis such as ascites, portal hypertension, and additional comorbidities. Using optimization of the Youden index analyses, the optimal cut-offs for diagnosis of significant fibrosis, severe fibrosis, and cirrhosis in our study were 1.53, 1.80 and 2.16 m/s, respectively. Although there are no known studies about the cut-off values for infants at present, previous studies have demonstrated cut-off values for adults. 9, [29] [30] [31] [32] A recent meta-analysis by Nierhoff et al suggested that the cut-off value for adults be 1.35 m/s for significant fibrosis, 1.61 m/s for severe fibrosis, and 1.87 m/s for cirrhosis. 31 Compared with our study, the cut-off values of meta-analysis were slightly lower, but the overall trend was same. We speculate that the higher values may be related to the degree of inflammation and corresponding pathological change. Previous studies have also reported that severe necroinflammation is a potential factor leading to higher stiffness measurements that are not accompanied by fibrosis. 33 In BA infants, severe intrahepatic cholestasis and portal inflammation are the most common pathological findings, which is definitely shown in our study (Figure 4 ). This progression is particularly rapid and severe, resulting in higher liver stiffness to a certain extent. As a consequence, liver stiffness of infants is slightly higher than that of adults with the same degree of liver fibrosis. There were differences in the selection of probe. Almost all studies used a 4-MHz curved array transducer for adults, whereas a 4-to 9-MHz linear transducer is more suitable in infants in our experience, which may lead to the slight rise of SWS in infants.
As indicated in Table 3 , the AUROC for the diagnosis of significant fibrosis, severe fibrosis, and cirrhosis was 0.823, 0.884 and 0.917, respectively. According to a diagnostic tool, in which it is defined as perfect if AUROC is 1, excellent if AUROC is larger than 0.9, and good if AUROC is larger than 0.8, ARFI imaging is a good diagnostic tool for significant and severe fibrosis, and an excellent diagnostic tool for cirrhosis. Our results were consistent with a meta-analysis of ARFI imaging reported in 2013 that included 36 studies with 3951 patients overall, in which diagnostic accuracies for each fibrosis degree were 0.84, 0.89 and 0.91, respectively. 31 Thus, the similarity in results suggests that ARFI imaging is an effective, noninvasive method for assessing different stages of liver fibrosis severity in infants, especially for the diagnosis of cirrhosis.
Acoustic radiation force impulse imaging has the advantage of being coupled with conventional ultrasound imaging in real time, well tolerated, and easy to be performed when compared with other methods in the evaluation of liver fibrosis. The high applicability indicates that it has the potential to become an important noninvasive adjunct to liver biopsy in infants, pending further validation. There are several limitations in our study. First, the sample size was relatively small. Second, ARFI imaging examination was performed by one sonographer, so its stability and reproducibility remains to be further confirmed. Third, we used the BattsLudwig scoring system for liver biopsy analysis in this study, which is widely used in adults with chronic liver diseases but is not completely suitable in infants with BA for its specific pathological changes. Future well-designed studies with a larger patient population are needed to further investigate this topic and validate the results of our current study.
In conclusion, ARFI imaging showed significant correlation with the severity of liver fibrosis, in comparison with liver biopsy pathology, and may be an effective noninvasive method for discerning different fibrosis stages from significant fibrosis to cirrhosis, which is definitely useful in liver fibrosis assessment, prognosis prediction, and clinical management in infants with BA preoperatively.
